<DOC>
	<DOC>NCT01190202</DOC>
	<brief_summary>The aim of this epidemiology study is to characterize in a standardized way malaria transmission intensity at the clinical trial centers participating in study 110021 (NCT00866619).</brief_summary>
	<brief_title>Epidemiology Study of Malaria Transmission Intensity in Africa</brief_title>
	<detailed_description>This study is a multicenter epidemiology study at centers that are participating in GSK's pivotal Phase III candidate malaria vaccine 110021 ( NCT00866619) trial and will involve 4 annual cross sectional surveys performed preferably at peak transmission. There will be no study vaccine administered in this epidemiology study.</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<criteria>Subjects who the investigator believes that they and/or their parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol. A male or female 6 months or older at the time of survey. Written informed consent obtained from the subject/from the parent(s)/ Legally Acceptable Representative(s) of the subject. Child in care. Previous or current participation in any malaria vaccine trial.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Plasmodium falciparum</keyword>
</DOC>